Licensed medicine
A regulator has licensed it for at least one use, in at least one country. That says nothing about uses outside the license.
This page is a stub
The wiki has this compound's identity from the My-Pepts library, its standing, and what PubMed holds for it. The article, with its studies read and cited, is not written yet. Until it is, the counts below say how much research exists, not what it found.
How strong is the evidence
How far it has climbed
Every medicine climbs the same ladder. Most compounds never reach the top, and where one stands says how much its claims can carry.
- Licensed medicine: Tirzepatide
A regulator has reviewed the trials and licensed it for a named use.
- Phase 3
Large randomized trials, often thousands of people, against placebo or a standard treatment.
- Phase 2
Mid-sized trials that measure dose against effect in people with the condition.
- Phase 1 and early human studies
First studies in people: safety, and how the body handles it.
- Cells and animals
Laboratory and animal work. An animal result is not a result in people.
- 2,794
- papers on PubMed
- 1,501
- of them in people
- 135
- randomized trials
- 1,024
- reviews
A count says how much has been published, not what it found. Counted on PubMed: 2026-11-16
Handling and reconstitution
From powder to a measured sample
The same four steps for any lyophilized vial. Laboratory handling, not use in a person.
1. Read the vial
The label gives the mass of peptide in the vial, in milligrams. That number is the start of every calculation.
2. Add the diluent
A measured volume of diluent goes in slowly, down the glass. Swirl gently; shaking can damage a peptide.
3. Work out the strength
Concentration is mass divided by volume: 10 mg in 2 mL is 5 mg per mL.
4. Measure the sample
Volume is the mass wanted divided by the concentration. On a U-100 syringe, 1 mL is 100 units.
The calculator below does the arithmetic and shows its working.
As powder
General practice for lyophilized peptides: keep the sealed vial frozen or refrigerated, dry and away from light, and follow the supplier's certificate of analysis.
In solution
Once in solution a peptide is kept refrigerated and used within the period the supplier states. A vial drawn from more than once needs a preserved diluent such as bacteriostatic water.
This is general practice for lyophilized peptides, not data on Tirzepatide itself. The batch's certificate of analysis and the supplier's sheet are the facts to go by. More on storage
Reconstitution calculator
Opens on vial sizes common for research peptides. Change any number. How the arithmetic works
Draw to
10 units
0.1 mL on a U-100 syringe
- Concentration
- 2.5 mg/mL
- Each unit holds
- 25 mcg
- Samples in the vial
- 20
- Sample
- 250 mcg
5 mg in 2 mL is 2.5 mg/mL. 250 mcg of that is 0.1 mL, which reads as 10 units. This is arithmetic for a vial of Tirzepatide; no amount here is a recommendation.
Tirzepatide: on PubMed
What PubMed held for Tirzepatide on November 16, 2026. A count says how much a compound has been studied, not what the studies found: how to read these numbers.
- 2,794
- papers
- 1,501
- in humans
- 146
- clinical trials
- 135
- randomized trials
Most relevant on PubMed
Listed by PubMed's own relevance ranking, trials and reviews first. The wiki has not read these into the article unless they are also among its sources.
- Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight
Randomized trialLook M, Dunn JP, Kushner RF, et al. Diabetes, obesity & metabolism, 2025. PMID 39996356
- Tirzepatide for Obesity Treatment and Diabetes Prevention
Randomized trialJastreboff AM, le Roux CW, Stefanski A, et al. The New England journal of medicine, 2025. PMID 39536238
- Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity
Randomized trialMalhotra A, Grunstein RR, Fietze I, et al. The New England journal of medicine, 2024. PMID 38912654
- Tirzepatide Once Weekly for the Treatment of Obesity
Randomized trialJastreboff AM, Aronne LJ, Ahmad NN, et al. The New England journal of medicine, 2022. PMID 35658024
- Discontinuing glucagon-like peptide-1 receptor agonists and body habitus: A systematic review and meta-analysis
Meta-analysisBerg S, Stickle H, Rose SJ, et al. Obesity reviews : an official journal of the International Association for the Study of Obesity, 2025. PMID 40186344
- Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial
Randomized trialAronne LJ, Sattar N, Horn DB, et al. JAMA, 2024. PMID 38078870
- Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
TrialAronne LJ, Horn DB, le Roux CW, et al. The New England journal of medicine, 2025. PMID 40353578
- Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial
Randomized trialDahl D, Onishi Y, Norwood P, et al. JAMA, 2022. PMID 35133415
Search used: ("Tirzepatide"[tiab]). Run it on PubMed
Research links
- PubMed (opens in a new tab)Every indexed paper, newest first
- ClinicalTrials.gov (opens in a new tab)Registered trials and their status
- Europe PMC (opens in a new tab)Full text where it is open access
- Google Scholar (opens in a new tab)Papers, preprints and who cites them
- PubChem (opens in a new tab)Structure, identifiers and properties
- YouTube (opens in a new tab)Talks and lectures. Check who is speaking
These open a search for Tirzepatide on each site. The wiki has not reviewed what they return: a video or a preprint is not a peer-reviewed result, and none of it is medical advice.
Also in Metabolic
Sold in blends: Tirzepatide + BPC-157